This article centers around a proposal outlining how research universities could leverage their intellectual property to help close the access gap for health innovations in poor countries. A recent deal between Emory University, Gilead Sciences, and Royalty Pharma is used as an example to illustrate how ‘equitable access licensing’ could be put into practice.
[BUT IT WASN’T! This is an example of where non-exclusive licensing would have had a big impact. Emory sold the rights for 525mil to private industry. Read source for details]
Closing the access gap for health innovations: an open licensing proposal for universities